NASDAQ:CERS - Cerus Stock Price, Forecast & News

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus Co. (NASDAQ:CERS) issued its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.01. The biotechnology company had revenue of $18 million for the quarter, compared to the consensus estimate of $17.69 million. Cerus had a negative net margin of 100.38% and a negative return on equity of 100.59%. Cerus's revenue was up 16.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.11) EPS. View Cerus' Earnings History.

Cerus issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $110.77 million.

3 analysts have issued 1 year price objectives for Cerus' shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate Cerus' stock price to reach $7.33 in the next year. This suggests a possible upside of 35.6% from the stock's current price. View Analyst Price Targets for Cerus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerus.

Media coverage about CERS stock has been trending negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cerus earned a daily sentiment score of -2.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Cerus.

Some companies that are related to Cerus include Align Technology (ALGN), Cooper Companies (COO), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Anika Therapeutics (ANIK), Antares Pharma (ATRS), OraSure Technologies (OSUR) and Utah Medical Products (UTMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Opko Health (OPK), Celldex Therapeutics (CLDX), Omeros (OMER), Grayscale Bitcoin Trust (Btc) (GBTC) and Aduro BioTech (ADRO).

Cerus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (6.96%), Nikko Asset Management Americas Inc. (6.15%), ARK Investment Management LLC (6.71%), State Street Corp (2.52%), Peregrine Capital Management LLC (1.70%) and Senvest Management LLC (1.26%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman. View Institutional Ownership Trends for Cerus.

CERS stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, King Luther Capital Management Corp, Bank of America Corp DE, Bamco Inc. NY, Principal Financial Group Inc., Senvest Management LLC, New York State Common Retirement Fund and UBS Group AG. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Insider Buying and Selling for Cerus.

CERS stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., ARK Investment Management LLC, State Street Corp, Peregrine Capital Management LLC, Jacobs Levy Equity Management Inc. and Millrace Asset Group Inc.. Company insiders that have bought Cerus stock in the last two years include Laurence M Corash, Timothy L Moore and William Mariner Greenman. View Insider Buying and Selling for Cerus.

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CERS stock can currently be purchased for approximately $5.41.

Cerus has a market capitalization of $859.54 million and generates $60.91 million in revenue each year. The biotechnology company earns $-57,560,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Cerus employs 240 workers across the globe.View Additional Information About Cerus.

The official website for Cerus is http://www.cerus.com/.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]